BCL2 and ataxia telangiectasia: Our findings demonstrating good CNS penetration for both the dual mTORC1/2 inhibitor, TAK-228 and the pan-BCL-2 family inhibitor, Obatoclax, and their efficacy in combination to extend survival in orthotopic models of AT/RT, demonstrate the potential of this novel combination therapy to improve outcomes in AT/RT.